COPENHAGEN, Denmark, May 23, 2023 – Bavarian Nordic A/S announced today that the Company s share capital has been increased by nominally DKK 555,430 as a consequence of employees’. | May 23, 2023
COPENHAGEN, Denmark, May 23, 2023 – Bavarian Nordic A/S has today received information about the following transactions of the company’s shares/related securities by persons holding. | May 23, 2023
The U.S. Centers for Disease Control and Prevention is urging people at high risk of mpox to get two doses of Bavarian Nordic s Jynneos vaccine, based on new evidence from a U.S. study showing. | May 18, 2023
COPENHAGEN, Denmark, May 17, 2023 – Bavarian Nordic A/S announces that the share buy-back program, which was announced and initiated on May 9, 2023, has now been terminated, as the intended. | May 17, 2023
COPENHAGEN, Denmark, May 15, 2023 – Bavarian Nordic A/S announced today that it has completed its acquisition of the travel vaccine portfolio from Emergent BioSolutions Inc. . With the. | May 15, 2023